A股異動 | 康泰生物逆勢漲6% 股價再創上市新高
格隆匯10月30日丨康泰生物(300601.SZ)持續拉昇,現報86.7元,漲幅6%,暫成交5.44億元,最新總市值559億,盤中最高見87.48元,再創上市新高。公司28日公告稱,前三季度歸屬於上市公司股東的淨利潤4.31億元,同比增長14.53%;第三季度歸屬於上市公司股東的淨利潤1.73億元,同比增長92.21%。中銀國際指,預計2019-2021年公司收入分別為23.03、29.82、40.92億元,對應歸母淨利分別為5.48、8.35、14.14億,對應PE96、63、37倍。目前行業集中度提升確定性高,龍頭企業在品種獲批、市場準入等方面存在顯著的溢價優勢,認為2021-2022年公司市值有望突破千億,維持增持評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.